|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
3.28(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
22,948 |
163,087 |
338,087 |
Total Sell Value |
$0 |
$1,362,031 |
$11,023,312 |
$20,394,162 |
Total People Sold |
0 |
2 |
4 |
4 |
Total Sell Transactions |
0 |
2 |
13 |
20 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bolzon Bradley J Phd |
Director |
|
2020-09-09 |
4 |
A |
$0.00 |
$0 |
D/D |
7,391 |
7,391 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2020-09-09 |
4 |
AS |
$0.00 |
$0 |
I/I |
(207,408) |
0 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2020-09-09 |
4 |
A |
$0.00 |
$0 |
I/I |
42,272 |
42,272 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2020-09-02 |
4 |
D |
$94.15 |
$73,343 |
D/D |
(779) |
169,968 |
|
- |
|
Tomsicek Michael John |
Chief Financial Officer |
|
2020-09-01 |
4 |
AS |
$91.39 |
$1,107,068 |
D/D |
(12,000) |
410 |
|
- |
|
Tomsicek Michael John |
Chief Financial Officer |
|
2020-09-01 |
4 |
OE |
$17.75 |
$213,000 |
D/D |
12,000 |
12,410 |
|
- |
|
Novak Rodger |
President |
|
2020-09-01 |
4 |
AS |
$91.54 |
$2,315,578 |
D/D |
(25,000) |
648,007 |
|
- |
|
Novak Rodger |
President |
|
2020-09-01 |
4 |
OE |
$14.00 |
$359,059 |
D/D |
25,000 |
673,007 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2020-09-01 |
4 |
S |
$91.27 |
$5,550,644 |
I/I |
(60,000) |
0 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2020-09-01 |
4 |
OE |
$13.62 |
$1,513,950 |
I/I |
60,000 |
60,000 |
|
- |
|
Novak Rodger |
President |
|
2020-08-19 |
4 |
AS |
$100.00 |
$2,500,000 |
D/D |
(25,000) |
648,007 |
|
- |
|
Novak Rodger |
President |
|
2020-08-19 |
4 |
OE |
$14.00 |
$350,000 |
D/D |
25,000 |
673,007 |
|
- |
|
Behbahani Ali |
Director |
|
2020-08-13 |
4 |
A |
$0.00 |
$0 |
I/I |
14 |
14 |
|
- |
|
Behbahani Ali |
Director |
|
2020-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
57 |
256 |
|
- |
|
Tomsicek Michael John |
Chief Financial Officer |
|
2020-08-03 |
4 |
AS |
$86.25 |
$1,040,919 |
D/D |
(12,000) |
410 |
|
- |
|
Tomsicek Michael John |
Chief Financial Officer |
|
2020-08-03 |
4 |
OE |
$17.75 |
$213,000 |
D/D |
12,000 |
12,410 |
|
- |
|
Novak Rodger |
President |
|
2020-07-07 |
4 |
AS |
$90.00 |
$2,250,000 |
D/D |
(25,000) |
648,007 |
|
- |
|
Novak Rodger |
President |
|
2020-07-07 |
4 |
OE |
$1.81 |
$281,907 |
D/D |
25,000 |
673,007 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2020-07-06 |
4 |
AS |
$82.16 |
$1,647,730 |
I/I |
(20,000) |
554,190 |
|
- |
|
Novak Rodger |
President |
|
2020-07-01 |
4 |
AS |
$80.00 |
$4,000,000 |
D/D |
(50,000) |
648,007 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2020-06-25 |
4 |
AS |
$75.18 |
$369,272 |
D/D |
(4,912) |
20,000 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2020-06-25 |
4 |
OE |
$12.57 |
$61,744 |
D/D |
4,912 |
24,912 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2020-06-24 |
4 |
AS |
$74.90 |
$4,942,292 |
D/D |
(65,088) |
20,000 |
|
- |
|
Klein Lawrence Otto |
CBO & COO |
|
2020-06-24 |
4 |
OE |
$5.86 |
$558,707 |
D/D |
65,088 |
46,422 |
|
- |
|
Novak Rodger |
President |
|
2020-06-23 |
4 |
AS |
$75.00 |
$3,750,000 |
D/D |
(50,000) |
698,007 |
|
- |
|
485 Records found
|
|
Page 8 of 20 |
|
|